This paper examines how structural recombination of business units within a firm impacts subsequent firm innovation. We argue that structural recombination is both a means for firms to unlock the potential for intraorganizational knowledge recombination and a source of disruption to the firm's...

Studying acquisitions in the US pharmaceutical industry, we first question how the alignment of acquirers’ innovation trajectories (as path-dependent or path-breaking change through the acquisition of targets with similar or distant innovations) with their own inventors’ pre-acquisition...